Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.
Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, describe how they have used the Beacon platform, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.
Find out how B Cell Antibody Discovery on the Beacon system can be used to rapidly screen human B cell to discover antibodies against difficult targets such as viruses.
At PEGS EU 2021, Abveris CEO Tracey Mullen shared a few important lessons learned through using the Beacon system for antibody discovery. She discussed how the Berkeley Lights Platform has enabled Abveris to focus on deeply screening their antibodies upstream and only pulling forward the most qualified and functionally relevant antibodies for re-expression.